Clinical trial · Interventional
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding ended
Summary
Brief summary (as posted)
The purpose of this study is to explore whether administration of preservative free artificial tears will decrease the level of detectable radioiodine in the tears and nasolacrimal duct system of patients undergoing radioiodine therapy for thyroid carcinoma and thus decrease the risk of developing radioactive iodine associated nasolacrimal duct obstruction.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radioactive Iodine Level | — | UNRESOLVED | — |
| Thyroid Carcinoma | Thyroid Gland Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Artificial Tears | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Preservative free artificial tears
- description
- Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
- interventionNames
- Drug: Artificial Tears
Primary outcomes (1)
- measure
- Change in Level of Radioactive Iodine in Tears
- timeFrame
- Over a 4 day period
- description
- The radioactive iodine activity level in the tears will be measured, as collected via contact lenses. Each patient will have a control eye and an experimental eye that received artificial tears. The control eye has no intervention. The radioactive iodine activity level will be measured over four days, with Day 1 occurring on the Day of systemic radioactive iodine therapy. On each of the four days, the level of radioactive iodine will be compared between the control and experimental eyes to see if there is a statistical difference between the control and experimental eyes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Radio-iodine therapy for thyroid cancer * Radioiodine therapy ≥100mCi * Patient wears soft contacts on both eyes Exclusion Criteria: * Use of eye drops, other than artificial tears * History of periocular trauma with tear duct involvement/lacrimal gland trauma * History of lacrimal drainage disease: canaliculitis, dacryocystitis * Prior radiotherapy * Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel) * Medical conditions that predispose to NLD stenosis * Sarcoid * Granulomatosis with polyangiitis * Chronic lymphocytic leukemia
References
Publications (1)
- DERIVEDLee IT, Grice JV, Ji X, Chen Q, Bischoff LA, Jessop AC, Barahimi B, Codere F, Mawn LA, Sobel RK. A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer. Thyroid. 2024 Jan;34(1):82-87. doi: 10.1089/thy.2023.0338. Epub 2023 Dec 11. PMID 37917111